#psychedelic-therapy

#psychedelic-therapy

Psychedelics like MDMA are being considered for treating treatment-resistant mental illnesses, despite facing challenges from regulatory bodies.

Psychiatrists are conducting trials using psychedelics in therapy as part of a multifaceted approach to treating mental health conditions.

Psychedelic therapy, particularly psilocybin, is emerging as a significant treatment option for anxiety in terminally ill patients.

Lykos Therapeutics faces scrutiny for its MDMA treatment for PTSD after accusations of misconduct and abuse, challenging its FDA application process.

Psychedelic therapy offers potential hope for first responders suffering mental health crises. They seek healing for trauma, anxiety, and depression through innovative treatments.

Ketamine-assisted psychotherapy maximizes healing through a structured process, emphasizing the importance of preparation and integration alongside medication.

The background of DOGE staff raises concerns about potential conflicts of interest in psychedelic therapy practices.

The FDA's rejection of MDMA-assisted therapy for PTSD was a significant setback for MAPS and the psychedelic research community.

U.S. regulators may approve MDMA (ecstasy) for PTSD treatment, a first in over two decades.

The Department of Veterans Affairs will research psychedelic therapies, notably ibogaine, for PTSD treatment.